Zoetis Inc.

ZTS

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001555280

B/C

on the B/C boundary of 305 graded peers in healthcare

rank 123 of 305; percentile 40.1; sampling error 2.8 points; lower is stronger

A B C D E


B/C, the elk



Scoreboard


Profitability	B/C	percentile 38.4
Solvency	C	percentile 56.7
Growth and financing	B/C	percentile 38.8
Reliability	0.94 AUC	filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets	total assets $15.5B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: fortress balance sheet
Inputs computable	8 of 13	
Graded from	filings received through Feb 12, 2026	284 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$79.08	2026-11-20; market equity $32.1B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

In order to sell our products, we must be able to produce and ship our products in sufficient quantities. Many of our products involve complex manufacturing processes and are sole-sourced from certain manufacturing sites. Minor deviations in our manufacturing or logistical processes, such as temperature excursions or improper package sealing, could result in delays, inventory shortages, unanticipated costs, product recalls, product liability and/or regulatory action. In addition, a number of factors could cause production interruptions that could result in launch delays, inventory shortages, recalls, unanticipated costs or issues with our supply agreements with third parties.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 38.4						
Gross profitability	44.0%	32.8%		28.7	346	2025-12-31
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(1.6%)	(6.7%)	77.9	756	2025-12-31
Gross margin stability, five years	0.7 pts	2.8 pts	8.5	237	2025-12-31
Solvency, sleeve percentile 56.7					
Altman Z double-prime	not computable	0.31			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	3.03x	2.68x	56.7	781	2025-12-31
Growth and financing, sleeve percentile 38.8					
Revenue growth, three-year compound	5.4%	9.6%	58.4	400	2025-12-31
Free cash flow growth, three-year compound	19.9%	11.1%	45.2	94	2025-12-31
Reinvestment rate	not computable	33.9%			
one or more required annual facts are missing					
Asset growth, three years	1.2%	3.2%	49.4	663	2025-12-31
Net share issuance, one year	(5.7%)	1.6%	2.4	626	2026-02-06

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
118	Fitlife Brands, Inc. (FTLF)	38.5	B/C	
119	Tenet Healthcare Corp. (THC)	38.8	B/C	
120	Myomo, Inc. (MYO)	39.1	B/C	fortress balance sheet
121	Establishment Labs Holdings Inc. (ESTA)	39.5	B/C	fortress balance sheet
122	Sanuwave Health, Inc. (SNWV)	39.8	B/C	
123	Zoetis Inc. (ZTS)	40.1	B/C	
124	LifeMD, Inc. (LFMD)	40.5	B/C	late filer
125	UroGen Pharma Ltd. (URGN)	40.8	B/C	distress
126	Lakeland Industries Inc. (LAKE)	41.1	B/C	late filer, fortress balance sheet
127	Bio-Techne Corp. (TECH)	41.4	B/C	fortress balance sheet
128	Artivion, Inc. (AORT)	41.8	B/C	

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(50.8%)	(1.7%)	15
Distance from 52-week high	(39.7%)	(33.0%)	44
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	7.1%	0.6%	86
Book value to price	0.10	0.29	24

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.29	0.38	42
Composite equity issuance, five years	(22.2%)	13.5%	8
Relative strength against the sector, log excess return	(0.88)	(0.19)	15
Twelve-month failure probability, CHS model	0.04%	0.06%	32

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 8 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.3B
Operating cash flow, four quarters	$2.7B
Months of runway	not finite
Days since last periodic filing	18 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$310.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$9.5B	2025-12-31	2026-02-12	10-K	26-000011
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.7B	2025-12-31	2026-02-12	10-K	26-000011
3	assets	us-gaap:Assets	$15.5B	2025-12-31	2026-02-12	10-K	26-000011
4	net income	us-gaap:NetIncomeLoss	$2.7B	2025-12-31	2026-02-12	10-K	26-000011
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.9B	2025-12-31	2026-02-12	10-K	26-000011
6	assets	us-gaap:Assets	$14.2B	2024-12-31	2026-02-12	10-K	26-000011
7	revenue	us-gaap:Revenues	$9.3B	2024-12-31	2026-02-12	10-K	26-000011
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.7B	2024-12-31	2026-02-12	10-K	26-000011
9	revenue	us-gaap:Revenues	$8.5B	2023-12-31	2026-02-12	10-K	26-000011
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.6B	2023-12-31	2026-02-12	10-K	26-000011
11	revenue	us-gaap:Revenues	$8.1B	2022-12-31	2025-02-13	10-K	25-000102
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.5B	2022-12-31	2025-02-13	10-K	25-000102
13	revenue	us-gaap:Revenues	$7.8B	2021-12-31	2024-02-13	10-K	24-000143
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.3B	2021-12-31	2024-02-13	10-K	24-000143
15	current assets	us-gaap:AssetsCurrent	$6.8B	2025-12-31	2026-02-12	10-K	26-000011
16	current liabilities	us-gaap:LiabilitiesCurrent	$2.2B	2025-12-31	2026-02-12	10-K	26-000011
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$621.0M	2025-12-31	2026-02-12	10-K	26-000011
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.0B	2024-12-31	2026-02-12	10-K	26-000011
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$655.0M	2024-12-31	2026-02-12	10-K	26-000011
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.4B	2023-12-31	2026-02-12	10-K	26-000011
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$732.0M	2023-12-31	2026-02-12	10-K	26-000011
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.9B	2022-12-31	2025-02-13	10-K	25-000102
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$586.0M	2022-12-31	2025-02-13	10-K	25-000102
24	assets	us-gaap:Assets	$14.3B	2023-12-31	2025-02-13	10-K	25-000102
25	assets	us-gaap:Assets	$14.9B	2022-12-31	2024-02-13	10-K	24-000143
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	422,127,709	2026-02-06	2026-02-12	10-K	26-000011

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	shares outstanding	dei:EntityCommonStockSharesOutstanding	447,791,917	2025-02-07	2025-02-13	10-K	25-000102	